Literature DB >> 21704103

Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants.

Suzanne J C Verhaegh1, Corné P de Vogel, Kristian Riesbeck, Eric R Lafontaine, Timothy F Murphy, Henri A Verbrugh, Vincent W V Jaddoe, Albert Hofman, Henriëtte A Moll, Alex van Belkum, John P Hays.   

Abstract

The primary Moraxella catarrhalis-specific humoral immune response, and its association with nasopharyngeal colonization, was studied in a cohort of infants from birth to 2 years of age. Results indicated that the levels of antigen-specific IgG, IgA and IgM showed extensive inter-individual variability over time, with IgM and IgA levels to all 9 recombinant domains, from 7 different OMPs, being relatively low throughout the study period. In contrast, the level of antigen-specific IgG was significantly higher for the recombinant domains Hag³⁵⁸⁻⁸⁵³, MID⁷⁶⁴⁻⁹¹³, MID⁹⁶²⁻¹²⁰⁰, UspA1⁵⁵⁷⁻⁷⁰⁴ and UspA2¹⁶⁵⁻³¹⁸ in cord blood compared to 6 months of age (P ≤ 0.001). This was a most likely a consequence of maternal transmission of antigen-specific IgG to newborn babies, possibly indicating a future role for these 3 surface antigens in the development of an effective humoral immune response to M. catarrhalis. Finally, at 2 years of age, the levels of antigen-specific IgG still remained far below that obtained from cord blood samples, indicating that the immune response to M. catarrhalis has not matured at 2 years of age. We provide evidence that a humoral antibody response to OMPs UspA1, UspA2 and Hag/MID may play a role in the immune response to community acquired M. catarrhalis colonization events.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704103     DOI: 10.1016/j.vaccine.2011.06.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  The Generation R Study: Biobank update 2015.

Authors:  Claudia J Kruithof; Marjolein N Kooijman; Cornelia M van Duijn; Oscar H Franco; Johan C de Jongste; Caroline C W Klaver; Johan P Mackenbach; Henriëtte A Moll; Hein Raat; Edmond H H M Rings; Fernando Rivadeneira; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Eppo B Wolvius; Albert Hofman; Vincent W V Jaddoe
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

Review 2.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

3.  Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Authors:  Igor C Borges; Dafne C Andrade; Maria Regina A Cardoso; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Olli Simell; Tuomas Jartti; Helena Käyhty; Olli Ruuskanen; Cristiana M Nascimento-Carvalho
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

4.  Serum antibody response to Moraxella catarrhalis proteins OMP CD, OppA, Msp22, Hag, and PilA2 after nasopharyngeal colonization and acute otitis media in children.

Authors:  Dabin Ren; Anthony L Almudevar; Timothy F Murphy; Eric R Lafontaine; Anthony A Campagnari; Nicole Luke-Marshall; Janet R Casey; Michael E Pichichero
Journal:  Vaccine       Date:  2015-09-21       Impact factor: 3.641

Review 5.  Panel 6: Vaccines.

Authors:  Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 3.497

Review 6.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  Vaccine targets against Moraxella catarrhalis.

Authors:  Dabin Ren; Michael E Pichichero
Journal:  Expert Opin Ther Targets       Date:  2015-08-26       Impact factor: 6.902

8.  Stringently Defined Otitis Prone Children Demonstrate Deficient Naturally Induced Mucosal Antibody Response to Moraxella catarrhalis Proteins.

Authors:  Dabin Ren; Timothy F Murphy; Eric R Lafontaine; Michael E Pichichero
Journal:  Front Immunol       Date:  2017-08-11       Impact factor: 7.561

9.  In Silico Prediction of a Multitope Vaccine against Moraxella catarrhalis: Reverse Vaccinology and Immunoinformatics.

Authors:  Mohamed A Soltan; Nada Elbassiouny; Helmy Gamal; Eslam B Elkaeed; Refaat A Eid; Muhammad Alaa Eldeen; Ahmed A Al-Karmalawy
Journal:  Vaccines (Basel)       Date:  2021-06-18

10.  Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model.

Authors:  Margarita Smidt; Patrick Bättig; Suzanne J C Verhaegh; Axel Niebisch; Markus Hanner; Sanja Selak; Wolfgang Schüler; Eva Morfeldt; Christel Hellberg; Eszter Nagy; Urban Lundberg; John P Hays; Andreas Meinke; Birgitta Henriques-Normark
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.